Sveinn Sölvason, President and CEO, comments:
"Sales in Q1 2025 amounted to USD 203 million and organic growth came in at 4% driven by a strong finish to the quarter.

Growth was strong in our Prosthetics & Neuro Orthotics segment supported by continued momentum and solid volume growth in EMEA and APAC regions, while the year started out softer in Americas following a strong end to 2024.

Our EBITDA margin for the quarter was 18%; up 1%-point from Q1 2024."

Embla will host a conference call on April 29, 2025 at 09:00 CET / 7:00 GMT / 3:00 EST.

A webcast will be available through the following link: Embla Medical Q1 2025 webcast

To participate in the telephone conference please use the dial-in details provided below:
DK: +45 78 76 84 90
SE: +46 31-311 50 03
UK: +44 20 3769 6819
US: +1 646 787 0157
Participant access code: 274982

• Download Company Announcement
• Download Investor Presentation